ArticleRespirology case reports2026
Tepotinib Therapy for Advanced MET Exon 14 Skipping NSCLC With Non-Dialysis End-Stage Renal Disease: A Case Report.
Article in Respirology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tepotinib Therapy for Advanced MET Exon 14 Skipping NSCLC With Non-Dialysis End-Stage Renal Disease: A Case Report.Respirology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tepotinib is an oral mesenchymal-epithelial transition factor (MET) tyrosine kinase inhibitor approved for advanced or metastatic MET exon 14 skipping non-small cell lung cancer (NSCLC). While no dose adjustment is required in patients with mild-to-moderate renal impairment, evidence in those with severe renal dysfunction remains limited. We report a case of advanced MET exon 14 skipping NSCLC in a patient with end-stage renal disease (ESRD) without dialysis who was successfully treated with tepotinib. During therapy, serum creatinine increased, whereas serum cystatin C remained stable, suggesting pseudo-acute kidney injury due to inhibition of renal tubular transporters. Tepotinib was resumed at a reduced dose without further renal deterioration, resulting in a partial tumour response. This case highlights the feasibility of tepotinib therapy in carefully selected patients with ESRD and underscores the clinical utility of incorporating complementary renal biomarkers, cystatin C, for guiding treatment decisions and avoiding unnecessary treatment discontinuation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.